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Abstract    
Mitochondrial DNA (mtDNA) association studies have been conducted for over a decade using the 
haplogroup (lineage) association method, but this frequently produces conflicting results. Here we 
analyzed complete mtDNA sequence data of Alzheimer’s disease (AD) patients and aged controls, from 
the United Kingdom (UK) and the United States (US), using a new "mutational load” method. We 
calculated a pathogenicity score for each of the non-synonymous substitutions of the mtDNA sequences 
to produce a “total mutational load” for each sequence, and compared the mutational loads of cases and 
controls. Using these mutational load measures, we found no evidence to support the cumulative role of 
mtDNA variants as a susceptibility factor in AD; that is, AD patients (UK and US cohorts) did not have 
higher “mutational loads” than controls. However, the US aged controls, who are significantly older than 
the UK ones, with many showing evidence of being healthy and having good cognition in old age, had 
significantly lower “mutational loads”. This finding suggests that low mtDNA mutational load is more 
prevalent in healthy older people.   
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1. Introduction 
The prevalence of Alzheimer's disease (AD), a neurodegenerative disorder characterized 
symptomatically by impaired memory, alterations to personality and decreased visual-spatial skills, is 
increasing as the population ages; this increase is especially pronounced in the western world, but will 
almost certainly become an increasingly global issue. Although there are a small number of families 
presenting with autosomal-dominant AD, more than 90% of AD cases are classified as sporadic-onset. 
Nevertheless, results from genome-wide association studies (GWAS) estimate that the heritability of 
sporadic AD may be as high as 80% (Harold et al. 2009; Wang et al. 2014), so this important issue is far 
from settled.  
 The neuropathology of AD is complex, and includes loss of neurons, central inflammation, as 
well as the formation of amyloid plaques and neurofibrillary tangles that impact on neuronal signaling 
(Blennow et al. 2006). Although the triggers that lead to AD remain largely unknown, there is 
considerable evidence for a pathological role played by abnormal mitochondrial function and 
oxidative stress in the etiopathogenesis of AD (Valla et al. 2006). In this regard, in the post-mortem 
brains of AD patients, progressive mitochondrial dysfunction in neurons was described, in addition to 
the more frequent occurrence of cytochrome oxidase (COX)-negative neurons, an indication of 
increased oxidative stress and impairment in the mitochondrial respiratory chain, compared to 
neurological controls (Cottrell et al. 2002). Despite such studies, whether mitochondrial dysfunction is 
causal in AD remains a matter of considerable debate (Howell et al. 2005), as is the question of 
whether inherited variants located on the mitochondrial chromosome play a role in the onset and 
progression of AD (Bi et al. 2015; Elson et al. 2006; Maruszak and Zekanowski 2011). “The current 
study investigated the role of inherited mtDNA population variants, to examine for a possible role for 
these variants in susceptibility to AD, by using recent computational methods, and applying a new 
model in an attempt to establish whether such an association exists. The work presented here does not 
look at somatic mtDNA mutations (Reeve et al. 2008; Reeve et al. 2009); that is, it does not consider 
mitochondrial dysfunction acquired on a cellular basis during an individual neurons during an 
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individual’s lifetime (Greaves et al. 2014).” 
Human mitochondrial DNA (mtDNA) encodes for 13 essential polypeptide components of the 
mitochondrial respiratory chain that generates adenosine triphosphate (ATP). Since mtDNA adheres to a 
strict maternal inheritance pattern, the evolution of mtDNA is characterised by the emergence of distinct 
lineages, called  haplogroups (Herrnstadt et al. 2002). In light of this unique inheritance pattern, it is 
worth considering hypotheses by which inherited mtDNA variants might contribute to common/complex 
diseases such as AD. Firstly, it has been claimed that a number of complex diseases associate 
significantly with one mtDNA haplogroup, suggesting that one or more haplogroup-associated 
polymorphisms modify the risk (or outcome) of disease (Figure 1 (red star)). Whilst there are recent 
studies that support a role for commonly-seen inherited mtDNA variants in AD (Maruszak et al. 2009), as 
well as in other age-related neurodegenerative conditions, such as Parkinson’s disease (PD) (Hudson et al. 
2014), these associations remain to be confirmed. In this regard, a recent meta-analysis failed to find a 
consistent association between common mtDNA variants and AD (Hudson et al. 2012); however, another 
recent study did find such an association, this time in a Chinese population (Bi et al. 2015). This 
discrepancy highlights the issue of haplogroup studies being complicated by the occurrence of mtDNA 
variants that occur multiple times during human evolution, a phenomenon termed homoplasy (Herrnstadt 
et al. 2002) (Figure 1 (purple stars)). Another complication confounding haplogroup association studies is 
the high level of population stratification obtained with mtDNA analyses, due to mtDNA having an 
effective population size of one quarter the size of autosomal nuclear alleles. High levels of population 
stratification result in difficulties assembling appropriate control groups for case control studies, perhaps 
even requiring geographical matching of controls (Salas 2015). Traditional mtDNA haplogroup 
association studies have considered only the most common variants that define major haplogroups, as 
complete sequence data is not normally available for study cohorts.  
As studies using traditional haplogroup association methods are likely to continue producing 
conflicting results, there is a need to develop and introduce new models, capable of determining if 
mtDNA variation is important in either the onset or course of complex human diseases. In this paper, we 
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explore a less frequently considered model in the context of mtDNA, one which also considers the impact 
of evolutionarily more recent variants (Elson et al. 2006; Hudson et al. 2014), or rare population variants 
that form the leaves of the human phylogeny (Figure 1 (yellow stars)). In this regard, rare variants that 
alter an amino acid have a higher likelihood of being mildly deleterious, as natural selection has had less 
opportunity to remove them from the population (Elson et al. 2004; Pereira et al. 2011). Importantly, the 
current analysis is not aimed at identifying whether a particular rare variant is more common in AD, but 
rather if rare variants as a group, in particular those with a higher likelihood of being mildly deleterious, 
are more common in the AD cases than in aged-controls. 
Improved computational methods have recently been developed for determining the impact of non-
synonymous changes on protein function, thereby increasing the power for finding differences between 
disease and control cohorts. An example of such a methodology is the analysis software program MutPred 
(Li et al. 2009), which has been validated in the context of mtDNA variation (Pereira et al. 2012; Pereira 
et al. 2011). MutPred is based upon the established SIFT (Sorting Intolerant From Tolerant) algorithm, 
which considers the gain or loss of 14 different structural and functional properties of proteins. While 
analysis tools such as MutPred (Li et al. 2009), or Ploythen2 (Adzhubei et al. 2010) alone are not 
sufficient in a diagnostic context (Elson et al. 2015; Yarham et al. 2011; Yarham et al. 2012). However 
the power of programs MutPred to differentiate between groups rich in deleterious variants and those 
consisting of benign polymorphic variants has been clearly demonstrated (Pereira et al. 2011).         
The analysis reported in the current paper used best-available methodology and an adapted hypothesis, 
to re-analyse a substantial complete sequence dual location case/cohort, which was first reported in 2006 
(Elson et al. 2006). Even after using these new methods and refinements of the hypothesis, the conclusion 
of this paper are in line with former work, namely that the frequency of rare mtDNA variation is not 
strikingly different in AD cases when compared to aged controls. This finding argues against a role of 
inherited germ-line mtDNA variants in AD. 
The most interesting result of the current study is that “mutational load” was significantly lower in the 
aged US controls, when compared to the UK controls. This is of interest since the US controls are 
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significantly older than those from the UK. In addition, the US controls were clinically identified as 
healthy older people, whereas there was only evidence of an absence of disease in the UK controls. This 
difference in age and evidence of good cognition between the two control groups allowed us to suggest 
that low mtDNA “mutational load” might be more common in “healthy” older individuals than previously 
anticipated.   
  
2. Methods and Materials 
The mtDNA sequences used in the current study were reported previously by Elson and colleagues 
(2006) and are publically available at: http://www.phylotree.org/mtDNA_seqs.htm (van Oven and Kayser 
2009). The sequences comprise two independent cohorts termed the MitoKor (MK-US) and Medical 
Research Council (MRC-UK) sequences. The MK-US sequence set comprises the complete mtDNA 
coding regions for 75 AD patients and 64 aged controls, while the MRC-UK set contains 70 AD patients 
and 64 controls. Only mtDNA sequences from one of the major European haplogroups (H, V, U, K, T, J, 
I, X, W) are used in the analysis. As reported previously, AD was confirmed in immunohistologically-
stained post-mortem brain sections by using standardised neuropathological criteria (Elson et al. 2006). 
All the examined brain tissue sections taken from control cases were free from AD-related disease 
neuropathologies (Elson et al. 2006). For the MRC-UK samples, samples were included as controls if the 
patient, in life, had never experienced neuropsychiatric- (e.g. dementia, depression or psychosis) or 
cardiovascular disease (including stroke). At the neuropathological level, only appropriate age-related 
changes was allowed, including the presence of some small-vessel disease. The MRC-UK control brains 
also had to have <2 tangles/mm2 in the cortical lobes and <5 senile plaques/mm2 to be included in the 
control cohort. The 64 MK-US control sequences were derived from three sample sets: (1) 13 autopsy-
confirmed brain samples that showed normal histology, with the patients from this group that had a mean 
age of 81 years; (2) 21 blood samples from a cohort of healthy elderly individuals (mean age = 88 years); 
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and (3) 30 blood samples taken from a cohort of individuals that were >80 years of age and evaluated as 
being cognitively normal over a period of at least 6 years (which extended up to 16 years). 
Coding-region mtDNA sequences were obtained and analyzed as previously described 
(Herrnstadt et al. 2002). This approach incorporates several quality control measures, including a 
four-fold redundancy to minimize sequencing errors. Sequencing was conducted in a forward 
and reverse direction, with a 50% overlap of fragments (Herrnstadt et al. 2002). “Mutational 
load” values are given as the mean ± SD (standard deviation). The scores were compared using a 
one-way ANOVA, followed by a Tukey post-hoc test. All statistical analyses were conducted 
using GraphPad Prism software (version 6.05, GraphPad Software, Inc, La Jolla, CA, USA). The 
following P-value designations were applied: ***P  <0.001, extremely significant; **P  ≤  0.01, 
highly significant; *P  ≤  0.05, significant and P  >  0.05, non-significant (n/s). The present study 
explores a possible role for rare inherited mtDNA mutations in the susceptibility to AD, building 
on our previously published work (Elson et al. 2006). Only substitutions that were operationally 
homoplasmic were analyzed, with the sequencing having been conducted by traditional Sanger 
methodology, as heteroplasmies lower than ~15% could not be reliably detected. However, this would 
not result in missing important variants in the context of a study focused on inherited population variants. 
Previous studies by mitochondrial clinics and diagnostic centres have shown that mtDNA deletions and 
mtDNA point mutations do not create a biochemical defect resulting in a clinical defect until a “threshold 
level” is exceed. This threshold level varies by mutation, but is >60% and can be as high as 90% (Tuppen 
et al. 2010). 
 
3. Results  
In order to assess the possible phenotypic impact of the variants in the cases compared to controls, we 
initially compiled a list of non-synonymous variants that were present exclusively in either the AD cases 
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or the aged controls. We then compared the global frequency of these non-synonymous variants using a 
dataset consisting of 30,589 complete human mtDNA sequences; this global mtDNA dataset is available 
from the  MitoMap database (updated 04/08/2015) (Lott et al. 2013).  The rationale for this comparison 
being that variants that are mildly deleterious are likely to be less frequent in the population as selection 
acts at a number of levels to remove them (Elson et al. 2004; Stewart et al. 2008).  Post-germline selection 
operating one mildly deleterious variants is relatively slow.  Therefore, a statistically significant increase 
in the frequency of rare mtDNA variants in AD cases, relative to controls, is evidence that the variants 
play a role in the etiology of the disease. An independent samples Student’s t-test was applied to 
determine whether a difference exists in the global frequency of the variants exclusive to the AD and 
those in control datasets. Results reveal no statistically significant difference (P = 0.355, n/s). However, 
this comparison has the drawback that it includes a number of haplogroup markers, which are relatively 
common in the population, but potentially different between the AD cases and controls due to sampling 
effects. This problem manifests even more acutely in traditional haplogroup association studies (Salas 
2015), where it is normally addressed by clumping together haplogroups with frequencies of less than 5% 
into a single group.   
In an attempt to avoid this problem, we ranked the data to consider the number of variants seen only in 
the AD cases or in the controls that were present at a frequency of <0.1% in the global dataset (Pereira et 
al. 2011). This approach allowed us to explore the possibility that very rare population variants 
cumulatively might be more common in AD patients than in aged controls, with mildly deleterious 
variants being expected to be less frequent in populations, as they are removed by natural selection. We 
observed 22 variants, present at a frequency of <0.1%, in the global database of 30,589 complete 
sequences in the AD patients, with 23 such variants being present in the control sequences, suggesting 
that there was no difference in the number of very rare variants across the two cohorts.  This finding 
supports the view that a methodology based solely on the frequency of the alleles is not able to reveal 
differences between cohorts of a moderate size.      
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Next, we used the program MutPred (Li et al. 2009) to assess the likely impact of all non-synonymous 
changes seen in the cohort. The MutPred algorithm uses sequence conservation and protein structure to 
make predictions about the impact of a non-synonymous change on protein function and is therefore a 
more sophisticated tool for detecting mildly deleterious variants than a pure frequency count, even one 
using such a large global dataset (Li et al. 2009).  
After calculating the MutPred scores for each variant, we summed the scores of the non-synonymous 
changes on each sequence to produce a “total mutational load”. Mutational loads are given for the 
different groups as means with SD. Suppl. Table 1 (a-d) shows the haplogroup assignment 
(Weissensteiner et al. 2016), number of variants and “mutational loads” for each of the sequences used in 
the current study.  The AD cases from the UK had a mean “total mutational load” of 1.798 ± 0.88, with 
those from the US that showed a very similar mean level (1.789 ± 0.89). The UK aged controls had a 
mean “total mutational load” of 2.273 ± 0.92, whilst the US controls had a notably lower mean load of 
1.456 ± 0.78. Comparing all four groups with a one-way ANOVA reveled an extremely significant 
difference (P < 0.0001), with a Tukey post-hoc test indicating a significant difference between the UK 
AD and control cases (P = 0.0096). However, contrary to prediction, the mutational loads of the controls 
were higher than those of the AD patients. This surprising difference was not replicated in the AD cases 
and controls from the US (P = 0.115, n/s). There was also a significant difference between the UK control 
group and the AD cases from the US (P = 0.0066), but again in the opposite direction to what would have 
been predicted. Finally, there was a striking difference between the two control cohorts (P < 0.0001) 
(Figure 2a). It is worth noting that the number of variants, including non-synonymous changes seen in an 
individual, is affected by the proximity of an individual's mtDNA sequence to the reference sequence 
(termed the “revised Cambridge Reference Sequence” (rCRS)) on the phylogeny (Bandelt et al. 2014). An 
example is the large number of variants reported for many African mtDNA sequences (Bandelt et al. 
2014; Herrnstadt et al. 2002). To account for this effect, an adjusted total mutational load was calculated 
by dividing the “total mutational load” of each sequence by the number of non-synonymous variants on 
that sequence, to obtain a metric that describes the average impact of mtDNA variation on an individual’s 
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mtDNA sequence. This adjustment allowed us to test if AD sufferers have, on average, non-synonymous 
mtDNA variants that were more deleterious than controls. However, an adjusted mutational load will still 
include haplogroup markers, and thus not be entirely free from haplogroup context. The “adjusted total 
mutational load” for the UK AD cases was 0.41 ± 0.062 with those from the US being 0.41 ± 0.041. The 
UK controls had an “adjusted total mutational load” of 0.41 ± 0.048 and those from the US had 0.41 ± 
0.071. Comparing the four groups using a one-way ANOVA reveled no significant differences (P = 
0.395, n/s) (Figure 2b). 
It is worth noting that the MutPred program designated scores of 0.5 or greater as being “actionable 
hypotheses” and those of 0.75 or greater as being “confident hypotheses”, which indicates the likelihood 
that the substitution has a deleterious effect on protein function, with those below 0.3 being most likely to 
be variants that do not impact protein function (Li et al. 2009; Pereira et al. 2011).  
A potential concern with the “total mutational load” and “adjusted total mutational load” methodology 
is that signal from a small number of potentially mildly deleterious mtDNA variants with high MutPred 
scores (>0.5) might be “averaged away” if an individual also has a large number of variants with low 
MutPred scores. Therefore, we decided to focus the analysis on the amino acids replacements that hold 
the strongest likelihood to exert a negative phenotypic effect. The UK AD cases had a mean “>0.5 total 
mutational load” of 0.52 ± 0.56 whilst those from the US were 0.58 ± 0.65. The UK controls that had a 
“>0.5 total mutational load” were 0.86 ± 0.71, with those from the US that was 0.3798 ± 0.47. Comparing 
all four groups using a one-way ANOVA revealed that there were significant differences (P < 0.0001), 
whilst application of a Tukey post-hoc test showed a significant difference between the UK AD and 
control cases (P = 0.0064), in the opposite direction to what was predicted. Once again this observation 
was not replicated in the AD cases and US controls (P = 0.576, n/s) (Figure 3a). Again, the analysis 
highlighted a very significant difference between the two control cohorts (P < 0.0001) (Figure 3a). When 
the “>0.5 total mutational load” was adjusted for the number of mtDNA variants seen in the sequences, an 
ANOVA revealed borderline significance (P = 0.054). A Tukey post-hoc test then revealed that the UK 
and US controls showed statistically significant differences (P = 0.0388), with the older, healthier 
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individuals showing a lower mutational load (Figure 3b). The “>0.5 total mutational load” and “>0.5 
adjusted mutational load” and the number of associated variants for each sequence used in this analysis is 
displayed in Suppl. Table 1 (a-d).   
4. Discussion   
A wealth of evidence suggests a central role of mitochondrial dysfunction and oxidative stress in AD 
pathology and other neurodegenerative diseases (Coskun et al. 2006; Cottrell et al. 2002); however, it is 
unresolved if inherited mtDNA variants are involved in the etiology of such diseases (Bi et al. 2015; Coto 
et al. 2011; Elson et al. 2006; Hudson et al. 2012; Maruszak et al. 2009). This lack of clarity is also seen 
in a number of other human diseases (e.g. Diabetes (Chinnery et al. 2007; Torroni et al. 1997)) where 
mtDNA variation is hypothesized to play a role. The traditional haplogroup association model has been 
applied to obtain evidence for an etiological role but the myriad conflicting results have been obtained.  
This impasse argues strongly for the development of new association models to connect mtDNA variation 
with common complex diseases (Salas 2015). The traditional haplogroup association model aims to detect 
differences in the frequency of major haplogroups between cases and disease controls, with haplogroups 
being defined by the presence or absence of ancient (common) population variants. MtDNA has a low 
effective population size when compared to nuclear alleles, due to both maternal inheritance and its 
haploid nature. This low effective population size of mtDNA can result in stratification of these ancient 
variants, creating differences between populations at different geographical locations solely due to genetic 
drift [31]. Therefore, clines in gene frequency might be highly revealing for investigations aimed at 
studying population history, but they are problematic in the context of mtDNA association studies. 
In this study, we applied new approaches that avoid some of the limitations and pitfalls of traditional 
haplogroup association studies. The “mutational load” approaches described here have more statistical 
power than traditional haplogroup association studies, as the mutational load analyses use fewer tests and 
allow the application of more powerful parametric statistical analysis. With the relatively large number of 
complete mtDNA sequences (n = 273) that were analyzed here, our study had 80% power to detect a 20% 
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difference in total mutational load between cases and controls at the 0.05 significance level. This level of 
power compares well to reported estimates of the power of haplogroup association studies (Samuels et al. 
2006).  Therefore, we propose that this method should be used – in conjunction with other approaches - in 
future mtDNA association studies. The advent of cheaper and more user-friendly tools for the analysis of 
next generation sequencing data will bring about a rise in analyses that use complete mtDNA sequence 
data to conduct “mutational load”-type analysis. 
Our work also supports the view that subsequent mtDNA association studies should analyze only 
complete mtDNA sequence data and that the effects of rare variants should be analyzed as a general rule. 
Critically, this novel method focuses on inherited variants with high MutPred scores. Variants with high 
MutPred scores tend to be rare variants at the tip (or leaves) of the phylogeny and are thus not prone to 
stratification (Elson et al. 2004; Pereira et al. 2011). Therefore, it is also suggested that use of metrics 
such as mutational load and adjusted mtDNA mutational load can help avoid the false positive 
associations seen in the past (Salas 2015), when studying the role of the mitochondrial chromosome in the 
onset and development of common/complex human disease.  
In terms of new models proposed for sequence data analysis, a model that considers only variants with 
a MutPred score >0.5 seems biologically most plausible. In addition, it can be argued that when using 
these variants, there is no longer a need to adjust for the position of the sequence on the phylogeny as 
very few common haplogroup-associated variants score above this level. As one only looks at variants of 
likely deleterious effect, with recent studies suggesting that natural selection has been equally efficient at 
removing deleterious variants in all lineages, these variants will be at the tips or leaves of the phylogeny 
in the vast majority of cases (Pereira et al. 2011).    
In summary, the current study used new “mtDNA mutational load” methods to determine if mtDNA 
variation might play a role in the susceptibility to AD. Application of such new methods do not support a 
link between either the combined effect of all non-synonymous mtDNA variants on a person’s mtDNA, 
nor the combined effect of variants predicted to be of deleterious effect in the susceptibility to AD. 
Additionally, an examination of the data does not suggest there is a sub-group of our AD patients within 
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the cohort that have a higher mutational load (Figures 1 and 2; Supplemental Tables (a-d)). This suggests 
that studies on larger cohorts, which apply the same methods, are likely to arrive at a similar conclusion, 
but this cannot be stated with certainty. Surprisingly, however, the results suggest a role for “low mtDNA 
load” in maintaining good cognition in older individuals, with the strongest difference being between the 
control cohorts from the two locations. This is of interest, as our previous analysis of this dataset reported 
that the US aged controls were significantly older than the UK aged controls, while the age of the AD 
cohort did not differ between the two countries. As we reported previously (Elson et al. 2006), the mean 
age (and SD) of the MRC control group was 77.2 ± 9.6 years, whereas the mean age of the MitoKor 
control group was 83.4 ± 5 years. A two-tailed t-test (without an assumption of equal SDs) indicates that 
the MitoKor control group is significantly older than the MRC controls. There was also evidence to 
support that a significant proportion of the US cohort had aged well. Thus US control cohort might 
represent a more stringently assessed collection of cases and examples of particularly healthy old age 
individuals (Elson et al. 2006). The significant difference in “>0.5 total mutational load” and “adjusted 
total mutational load” in the UK and US controls suggests that mtDNA genotypes with fewer mildly 
deleterious mutations might be more common in the healthy old, as compared to the old that are simply 
free from disease, and thus low mtDNA mutational loads might be neuroprotective. This important 
finding merits additional investigation and analysis. 
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Figure 1 
Schematic representation of the European phylogeny, showing the nine major haplogroups. Stars 
illustrate the hypothesis that might link mtDNA variation to disease. (i) Red star – the traditional 
haplogroup association hypothesis, a single common variant affects susceptibility or is protective; (ii) 
purple stars – how the traditional haplogroup association hypothesis might be complicated by the 
occurrence of such a variant more than once on the phylogeny, a homoplasy; and (iii) yellow stars – how 
there might be a cumulative effect of multiple rare variants.    
Figure 2  
(a) Total mutational loads using all non-synonymous substitutions for the AD cases and controls in 
the UK and US cohorts. Comparing all four groups with a one-way ANOVA revealed an extremely 
significant differences (***P < 0.0001), with a Tukey post-hoc test showing a highly significant 
difference between the UK AD and control cases (**P = 0.0096), which was not replicated when the AD 
and control cohort from the US was analysed (P = 0.115, n/s). Additionally, a difference was seen 
between the two control cohorts from the two continents (***P < 0.0001). (b) Adjusted mtDNA 
mutational loads using all non-synonymous substitution (total load per sequence/number of 
variants per sequence). No significant differences were observed.  
Figure 3 
(a) Mutational loads, including only those using all non-synonymous substitutions with MutPred 
scores >0.5 in AD cases and controls, in both the UK and US cohorts. A highly significant difference 
was seen between UK AD and control cases (**P = 0.0064), but not in the replication cohort from the 
US. Again there was an extremely significant difference seen between the two control cohorts (***P < 
0.0001). (b) Adjusted mtDNA mutational loads (including only those variants with MutPred scores >0.5), 
in AD cases and controls from the UK and US cohorts showed the only significant difference after 
correcting for multiple comparisons between the controls from the US and the UK (*P = 0.0388).    
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Supplemental tables (a-d): Raw values by sequence for all the analysis conducted in this manuscript.  
 
 
 
 22 
 
 
 
 
 
 23 
 
 
 
 24 
 
